BridgeMD
Compares treatment options for Multiple Myeloma
Official title A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT07518186
What this study is testing
What is JNJ-79635322?
JNJ-79635322 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for multiple myeloma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group...
- Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication
- Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration...
You likely can't join if
- Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully...
- Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients
- Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other...
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected...
The study team makes the final eligibility decision.
Where it's taking place
- Springdale, Arkansas, United States
- Los Angeles, California, United States
- Atlanta, Georgia, United States
- Omaha, Nebraska, United States
- East Brunswick, New Jersey, United States
- Santa Fe, New Mexico, United States
- Mineola, New York, United States
- New York, New York, United States
- Shirley, New York, United States
- Canton, Ohio, United States
- Cincinnati, Ohio, United States
- Darlinghurst, Australia
- Haifa, Israel
- Petah Tikva, Israel
- Ramat Gan, Israel
- Tel Aviv, Israel
- Matsuyama, Japan
- Okayama, Japan
- Tokyo, Japan
- Yokohama, Japan
+ 6 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Springdale, Arkansas, United States; Los Angeles, California, United States; Atlanta, Georgia, United States; Omaha, Nebraska, United States; East Brunswick, New Jersey, United States; Santa Fe, New Mexico, United States and 20 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.